CEMIP promotes gefitinib resistance in lung cancer with EGFR-mutation possibly through forming a stable complex CEMIP/c-MYC

While gefitinib greatly improves the prognosis of lung cancer patients with epidermal growth factor receptor (EGFR) mutation, its inevitable resistance severely diminishes therapeutic efficacy. Cell migration-inducing protein (CEMIP) might interact with cellular MYC proto-oncogene (c-MYC) to synergi...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Li Li, Jiaxiu Xie, Jinxing Liang, Hua Su, Xiaoju Shen, Xiaoxiang Mo, Xinli Lin, Weidan Tan, Kun Wu, Fucui Zhu, Li Wang, Ying Liu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2026-01-01
Edice:	BBA Advances
Témata:	LUAD CEMIP c-MYC Gefitinib Chemo-resistance
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2667160325000390
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!